The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”
|Articles|May 23, 2012
First Cancer-Specific ACO Launches
Advertisement
The best business model for oncology care is not yet obvious to me. But it is crystal clear that innovative new models are being hatched before our eyes: First, the oncology medical home and now, the cancer-specific accountable care organization.
As reported in OT last year, The US Oncology Network had hoped that the federal government would allow cancer-specific ACOs. That idea did not fly. But US Oncology was apparently undaunted: One of its affiliates has announced its own ACO in conjunction with a private insurer and a big health system.
Read the full story:
Source: Oncology Times
Advertisement
Related to this article
At ASN Kidney Week 2026, experts said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.
FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Advertisement
Advertisement
Trending on AJMC
1
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
Menin Inhibitors in AML: In NYC, Experts Map the Path From Academic Centers to Community Care
4
Youths With Depression Face Higher Odds of Prescription Drug Misuse
5